Page last updated: 2024-10-18

dihydroxyphenylalanine and Glioblastoma with Sarcomatous Component

dihydroxyphenylalanine has been researched along with Glioblastoma with Sarcomatous Component in 1 studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leff, SE1
Rendahl, KG1
Spratt, SK1
Kang, UJ1
Mandel, RJ1

Other Studies

1 other study available for dihydroxyphenylalanine and Glioblastoma with Sarcomatous Component

ArticleYear
In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
    Experimental neurology, 1998, Volume: 151, Issue:2

    Topics: 3T3 Cells; Animals; Antioxidants; Antiparkinson Agents; Apomorphine; Behavior, Animal; Biopterins; C

1998